[The effectiveness of molixan as a means of correction of chemoradiation therapy negative manifestations in patients with oropharyngeal cancer].

The effectiveness of the peptide immunomodulator molixan as a means of support and correction of chemoradiation therapy of oral mucositis have been studied in 36 patients with primary regional cancer of the oral mucosa and the oropharynx. Combined chemotherapy of patients with cisplatin and standard radiotherapy was associated with progression of oral mucositis and hematopoietic disorders which manifested themselves in the form of neutro-, lympho- and thrombocytopenia. Therapeutic intramuscular application of molixan at a dose of 60 mg once a day after a fraction of irradiation made it possible to reduce the severity of oral mucositis (from grade III-IV to grade I-II), as well as to maintain in patients a higher level of white blood cells and platelets in the blood, which made it possible to complete the planned course of chemoradiation therapy.